ArticleCell reports2018
Mutant IDH1 Promotes Glioma Formation In Vivo.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 116 citations in OpenAlex.
- Gliomas phenocopy an inborn error of metabolism to drive neuronal activity and tumor growth.Cell · 2026Article
- Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma.Science translational medicine · 2026Article
- Translational Models for Glioblastoma: Revolutionizing Drug Development and Personalized Medicine through Clinical Insights.Theranostics · 2026Review
- Advances in the management of patients with IDH-mutant glioma.The oncologist · 2025Review
- Carcinogenesis: An Alternative Hypothesis Comparing Mutagenic Versus Metabolic Models.Biology · 2025Review
- New alleles of D-2-hydroxyglutarate dehydrogenase enable studies of oncometabolite function in Drosophila melanogaster.G3 (Bethesda, Md.) · 2025Article
- Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models.The Journal of biological chemistry · 2025Article
- A genetically encoded fluorescent sensor enables sensitive and specific detection of IDH mutant associated oncometabolite D-2-hydroxyglutarate.BMC cancer · 2025Article
- Mutant IDH impairs chromatin binding by PDGFB to promote chromosome instability.bioRxiv : the preprint server for biology · 2025Article
- Article
- IDH1 and ATRX mutations synergistically modulate cell proliferation and ferroptosis in glioblastoma cells.American journal of cancer research · 2025Article
- Rodent models of tumours of the central nervous system.Molecular oncology · 2024Review
- FAM109B plays a tumorigenic role in low-grade gliomas and is associated with tumor-associated macrophages (TAMs).Journal of translational medicine · 2024Article
- Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma.Acta neuropathologica · 2024Review
- IDH inhibition in gliomas: from preclinical models to clinical trials.Nature reviews. Neurology · 2024Review
- Article
- Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma.Acta neuropathologica communications · 2023Article
- The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches.Biochemical Society transactions · 2023Review
- Metabolic Rewiring in Adult-Type Diffuse Gliomas.International journal of molecular sciences · 2023Review
- Stalled oligodendrocyte differentiation in IDH-mutant gliomas.Genome medicine · 2023Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Beatrice PhilipHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA.
Diana X YuHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA.
Mark R SilvisHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA.
Clifford H ShinHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA.
James P RobinsonHormel Institute, University of Minnesota, 801 16(th) Avenue NE, Austin, MN 55912, USA.
Gemma L RobinsonHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA.
Adam E WelkerHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA.
Stephanie N AngelHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA.
Sheryl R TrippARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT 84108, USA.
Joshua A SonnenARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT 84108, USA; Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA.
Matthew W VanBrocklinHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA.
Richard J GibbonsMRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Ryan E LooperDepartment of Chemistry, University of Utah, Salt Lake City, UT 84112, USA.
Howard ColmanHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Neurosurgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA.
Sheri L HolmenHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA. Electronic address: sheri.holmen@hci.utah.edu.
University of Utah · USHuntsman Cancer Institute · USARUP Institute for Clinical and Experimental PathologyHormel (United States) · USMRC Weatherall Institute of Molecular Medicine · GB
Funding
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6MDefining the role of mutant IDH in glioma initiation and maintenanceR01NS075155 · NINDS · UNIVERSITY OF UTAH · PI HOLMEN, SHERI L · 2011 to 2016
$1.7MDefining the role of BRAF in glioma initiation and maintenanceR01NS073870 · NINDS · UNIVERSITY OF UTAH · PI HOLMEN, SHERI L · 2011 to 2016
$1.7MCharacterizing HBEGF in glioma formation and maintenanceF30CA203096 · NCI · UNIVERSITY OF UTAH · PI SHIN, CLIFFORD · 2016 to 2018
$94kMedical Research Council MC_UU_00016/3NCI NIH HHS F30 CA203096NCI NIH HHS P30 CA042014NINDS NIH HHS R01 NS073870NINDS NIH HHS R01 NS075155
Abstract
Isocitrate dehydrogenase 1 (IDH1) is the most commonly mutated gene in grade II-III glioma and secondary glioblastoma (GBM). A causal role for IDH1
Indexed as
Mutation, MissenseAmino Acid SubstitutionAnimalsAstrocytesCarcinogenesisGliomaHumansIsocitrate DehydrogenaseMiceMice, TransgenicNeoplasm ProteinsIdh1 protein, mouseIsocitrate DehydrogenaseNeoplasm ProteinsAtrxCdkn2agliomaIDH1mouse modelPtenRCAS/TVA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.